Agios to Present at Upcoming Investor Conferences

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO), a pioneer in cellular metabolism and PK activation therapies for rare diseases, has announced upcoming management presentations at two major investor conferences in March 2025.

The company will participate in:

• A fireside chat at the Leerink Global Healthcare Conference 2025 on March 11, 2025, at 10:50 a.m. ET
• A fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 12:30 p.m. ET

Both presentations will be available via live webcast on the Investors section of Agios's website under 'Events & Presentations'. Replay recordings will remain accessible for a minimum of two weeks after each presentation.

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences:

• Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m. ET
  
• Barclays 27^th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 12, 2025, at 12:30 p.m. ET
  

The live webcast for each event will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. Replays of the webcasts will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com

FAQ

When is Agios Pharmaceuticals (AGIO) presenting at the Leerink Global Healthcare Conference 2025?

Agios will present at the Leerink Conference on Tuesday, March 11, 2025, at 10:50 a.m. ET.

What time is AGIO's presentation at the Barclays Global Healthcare Conference in March 2025?

AGIO will present at the Barclays Conference on Wednesday, March 12, 2025, at 12:30 p.m. ET.

How long will AGIO's March 2025 investor conference webcasts be available for replay?

The webcasts will be archived on Agios's website for at least two weeks following each presentation.

Where can investors access AGIO's March 2025 conference presentations?

The presentations can be accessed via live webcast on the Investors section of Agios's website (www.agios.com) under Events & Presentations.